TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have persistent, recurrent, or primary Stage IVB carcinoma of the cervix not amenable to curative therapy with either surgery and/or radiation.~* Patients must have biopsy proven squamous cell, adenosquamous, or adenocarcinoma histology.~* Patients do not require measurable disease.~* Patients must have adequate organ function defined by laboratory work.~* Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.~* Patients must have recovered from any effects attributable to surgery, radiation, or chemoradiotherapy. A minimum of six weeks shall have passed since the last administration of chemoradiotherapy or three weeks for radiation therapy alone.~* Patients must be free of clinically significant infections.~* Patients must be age 19 or greater and have signed informed consent.~Exclusion Criteria:~* Patients who are pregnant or lactating.~* Patients with history of other malignancies (except non-melanoma skin cancer) within the last 5 years are ineligible.~* Patients with non-squamous, adenosquamous, or adenocarcinoma histology.~* Patients with bilateral hydronephrosis that cannot be alleviated by ureteral stents or percutaneous drainage.~* Patients currently receiving any or having received other investigational agents within the last 30 days are ineligible.~* Patients with known hypersensitivity to topotecan or cisplatin.~* Patients with craniospinal metastases.~* Patients with uncontrolled current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, serious peripheral neuropathy, or psychiatric illness/social situations that would limit or preclude compliance with study requirements are ineligible.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Response of Preterm Infants to Multisensory Stimuli

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn gestational age 32 0/7 weeks to 34 6/7 weeks~* Born at university hospital Geneva~* French speaking parents~* Out of incubator~* Signed consent~Exclusion Criteria:~* Newborn with one of the above conditions:~* Congenital malformation~* intraventricular hemorrhage grade III or IV~* white matter abnormality~* anti-epileptic or sedative drugs~* altered consciousness level~* Infant requiring respiratory support~* psychiatric disorders in the mother or antenatal use of psychoactive drugs~* Bilateral absent otoacoustic emissions and/or auditory evoked potential~* Parents refusal to participate

- Gender: ALL
- Minimum Age: 32 Weeks
- Maximum Age: 35 Weeks
- Healthy Volunteers: f

Study Arms:
- Voice only then distraction (Type: OTHER): First intervention: mother's voice without tactile stimuli Second intervention: mother's voice with tactile stimuli
- Distraction then voice only (Type: OTHER): First intervention: mother's voice with tactile stimuli Second intervention: mother's voice without tactile stimuli

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lumen Apposing Metal Stents vs Lumen Apposing Metal Stent Plus Double Pigtail Stent for Endoscopic Drainage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female patients between the ages of 18 and 80~* Must be presenting with symptomatic pancreatic fluid collections~* Scheduled to undergo endoscopic ultrasound (EUS)-guided drainage of PFCs with LAMS placement at Vanderbilt Medical Center as part of routine care~* Willing and able to give informed consent~Exclusion Criteria:~* Unwilling/unable to give informed consent~* Patients with PFCs consisting of \< 30% solid component as assessed at the time of EUS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lumen Apposing Metal Stent (LAMS) (Type: ACTIVE_COMPARATOR): Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
- LAMS plus double pigtail stent (Type: ACTIVE_COMPARATOR): Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years~* Patients giving their informed consent to participate to the study and to the use of their health data~* Patients with two or more SIRS criteria (hyperthermia, or hypothermia, tachycardia, tachypnea, leucocytosis or leukopenia )~* Patients treated with antibiotic therapy in the last 4 weeks and with central venous catheter~* Patients with at least one of these conditions ( cortisone therapy/ immunosuppressive agents, total parenteral nutrition, urinary catheter, anticancer chemotherapy and major surgery in the last 3 weeks, acute pancreatitis, diabetes mellitus, liver diseases, dialysis)~Exclusion Criteria:~* Patients with ALT, AST, bilirubin \> 3 times the upper limit of normal~* Patients enrolled in other interventional clinical studies~* Patients treated with echinocandin or azolic or polyene at the time of the enrolment~* Pregnancy or breastfeeding~* Neutropenic patients~* HIV positive patients~* Central nervous system events

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with suspicion of invasive candidiasis (Type: EXPERIMENTAL): Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cubicin(R) for Complicated Post-surgical Wound Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Read and signed informed consent form~* female of childbearing potential, negative pregnancy test result~* Confirmed diagnosis of post-surgical wound infections known or suspected (based on Gram stain) to be due to Gram-positive organisms obtained within 3 calendar days prior to first dose of study medication~* Onset of surgical wound infection within 30 days after surgery~* At least three clinical signs and symptoms of skin infection~Exclusion Criteria:~* previous systemic antimicrobial therapy exceeding 24 hours duration administered anytime during 72 hours prior to the first dose of study drug~* Uncomplicated surgical infections (eg, stitch abscesses)~* osteomyelitis, pneumonia, bacteremia, endocarditis, or urinary tract infection~* Any type of space infection~* Conditions requiring surgical removal of wound infection~* necrotizing fasciitis, synergistic gangrene, Clostridial myonecrosis (gas gangrene), or Fournier's gangrene;~* Foreign material involved in the post-surgical wound infection~* Known to be allergic or intolerant to study medication~* Creatinine Clearance (CLCR) \<30 mL/min~* history of neurological disease (eg, Guillain-Barré, multiple sclerosis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: REBEAT Resynchronisation and Beta-Blocker European Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic heart failure and indication for cardiac resynchronization therapy (CRT), Hemodynamic stability with documented intolerance to beta-blocker therapy or treatment with beta-blocking agents at sub-optimal dosages (\<25% of optimal dosage).~Exclusion Criteria:~* chronic atrial fibrillation; indications for permanent antibradycardia pacing; mechanical tricuspid valve; Severe aortic stenosis or other primary valve disease causing cardiomyopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Moderated Blood Flow Restriction After Anterior Cruciate Ligament Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between 18-30 years of age.~* Diagnosis of isolated anterior cruciate ligament (ACL) tear and pending ACL reconstruction.~Exclusion Criteria:~* age \<18 years old or \>30 years old~* Multi-ligament knee injury~* Revision ACL reconstruction~* History or peripheral vascular disease~* History of deep vein thrombosis or pulmonary embolism~* Any contraindication to moderated blood flow restriction therapy~* Inability to comply with post-operative ACL reconstruction rehabilitation~* If meniscal repair or a cartilage procedure is performed at the time of surgery that would preclude the patient from being able to follow the standard post-operative ACL rehabilitation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Standard rehabilitation (Type: ACTIVE_COMPARATOR): Patients will receive standard post-operative ACL rehabilitation
- Delfi moderated blood flow restriction (Type: EXPERIMENTAL): Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed progressive supratentorial anaplastic astrocytoma or glioblastoma multiforme~* No multifocal disease or leptomeningeal dissemination of tumor~* No evidence of tumor crossing midline~* Limited intraventricular involvement~* Measurable unilateral mass at least 10 mm by contrast-enhanced MRI~* Received prior involved-field radiotherapy as a component of prior therapy~* Amenable to and in need of significant debulking~PATIENT CHARACTERISTICS:~Age~* 3 to 21~Performance status~* Karnofsky 60-100% OR~* Lansky 60-100%~Life expectancy~* More than 8 weeks~Hematopoietic~* Absolute neutrophil count greater than 1,000/mm3\*~* Platelet count greater than 100,000/mm3\*~* Hemoglobin greater than 8 g/dL (transfusions allowed) NOTE: \* Transfusion independent~Hepatic~* Bilirubin no greater than 1.5 times normal~* AST and ALT less than 3 times normal~* Albumin at least 2 g/dL~* No overt hepatic disease~Renal~* Creatinine clearance no greater than 1.5 times normal OR~* Glomerular filtration rate greater than 70 mL/min~* No overt renal disease~Cardiovascular~* No overt cardiac disease~Pulmonary~* No overt pulmonary disease~Other~* Neurological deficits must be stable for at least the past week~* No uncontrolled infection~* No known hypersensitivity to nitrosoureas or polyethylene glycol~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 6 months since prior bone marrow transplantation~* More than 2 weeks since prior colony-stimulating growth factors (e.g., filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa)~Chemotherapy~* No more than 2 prior cytotoxic chemotherapy regimens~* No more than 3 prior chemotherapy regimens total~* More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered~* Prior systemic carmustine (or other nitrosourea) allowed provided patient did not experience non-hematopoietic grade III/IV toxicity~Endocrine therapy~* Concurrent dexamethasone allowed if on a stable dose for at least the past week~Radiotherapy~* See Disease Characteristics~* At least 3 months since prior radiotherapy~* No prior craniospinal irradiation for metastatic disease~Surgery~* See Disease Characteristics~* Prior biopsy or cytoreductive surgery allowed~Other~* Concurrent anticonvulsants allowed~* No other concurrent anticancer or investigational drugs

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Osteoporosis and Colles Fracture

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Colles Fracture Women over 40 years Informed consent-~Exclusion Criteria:~High Energy Fracture Deceases or conditions that makes the participant unable to contribute to the investigation-

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* woman \>= 18 years~* pain (median VAS \>=3 on the week prior to inclusion)~* mastectomy or tumorectomy with axillary dissection \<= 12 months~* PS \<=2~* able to write, understand and read French~* signed informed consent~Exclusion Criteria:~* no pain~* immediate breast reconstruction~* history of cognitive or psychiatric troubles

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- osteopathy + conventional analgesic treatments (Type: EXPERIMENTAL): None
- conventional analgesic treatments (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute asthma exacerbation or croup (laryngotracheitis) in the Vanderbilt Children's Hospital Emergency Department~* Age 1 to 7 years~* Dexamethasone treatment indicated~* No other acute or chronic process accounting for signs and symptoms (e.g., foreign body aspiration, pneumonia, cystic fibrosis)~* Have not received systemic corticosteroid for current episode prior to enrollment~Exclusion Criteria:~* Allergy to dexamethasone or apple sauce and pudding~* Unable to take medication orally

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone IV for PO (Type: EXPERIMENTAL): Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
- Dexamethasone crushed tablets (Type: ACTIVE_COMPARATOR): Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Participants were recruited and enrolled at VACT West Haven, CT. Participants are aged 18 and older and have 3 months or more of continuous opioid therapy for chronic pain. Participants are actively prescribed 30-100mg of morphine equivalent opioid dose based on pharmacy records. Primary Care Providers will assent for patient participation.~Inclusion Criteria:~* Aged 18 and older~* 3 months of continuous opioid therapy for chronic pain;~* 30-100 mg morphine equivalent daily opioid dose based on pharmacy records of standing and as needed opioids prescribed.~* 28 (out of 70) on the 7-item Brief Pain Inventory (BPI) functional interference subscale at screening~* Numerical pain rating of 4 or greater (i.e., moderate pain or greater) at screening on the 11-point pain numerical rating scale (NRS)~* Females must (a) be using birth control pills or depo provera injections, or have an intrauterine device; or (b) be post-menopausal, or (c) have undergone surgically sterilization.~* Primary care provider's (PCP) assent for patient participation, ascertained via encrypted email or in-person query.~Exclusion Criteria:~* DSM-IV defined substance use disorder, except nicotine dependence. Participants known to using marijuana, including those who are apparently legally authorized to use marijuana by non-VHA providers, will be excluded since opioid dose escalation in regular marijuana users is contraindicated.~* Opioid therapy for palliative care~* Participation in another investigational pharmaceutical trial within 30 days of screening~* Pregnancy or lactation~* Recently decompensated medical illness necessitating inpatient hospitalization (past 30 days)~* Transaminases (aspartate aminotransferase/alanine aminotransferase) greater than five times the upper limit of normal within 90 days of assessment phase~* Not well-controlled psychiatric symptoms at the time of physician assessment, including suicidal ideation or untreated psychosis; or recently decompensated psychiatric illness necessitating inpatient hospitalization (past 30 days).~* Use of a moderate to strong CYP3A4 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- buprenorphine/naloxone (Type: EXPERIMENTAL): induction onto buprenorphine/naloxone from opioid treatment
- opioid dose escalation (Type: ACTIVE_COMPARATOR): increase of up to 25% of current opioid dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PK Intravenous Lidocaine Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female children 3-15 years of age~* ASA physical status 1-3~* scheduled for colorectal surgery with abdominal incision~Exclusion Criteria:~* ASA physical status \> 3~* postoperative intubation planned ahead of surgery~* history of chronic use of opioid (use longer than 3 months)~* history of hepatic, renal, or cardiac failure~* history of significant liver disease including liver failure, acute or chronic hepatitis, hepatomegaly, portal hypertension and elevated liver enzymes~* history of organ transplant~* BMI \> 30~* history of cardiac arrhythmia~* history of long QT syndrome~* history of allergic reaction to lidocaine or similar agents~* history of seizure disorder~* patient without PICC or other central access with contraindication to inhalation induction~* family history or known patient susceptibility to malignant hyperthermia

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues